Fresh Frozen Plasma Indications and Evidence-Based Use
AABB evidence-based plasma transfusion guidelines recommend plasma for trauma patients requiring massive transfusion (weak recommendation, moderate-quality evidence). [1] AABB guidelines recommend against using plasma in several non-bleeding or non–massive-transfusion settings due to limited evidence of benefit and risks of harm. [1]
Medication Selection Algorithm
- Trauma with massive transfusion: plasma use is suggested. [1]
- Warfarin anticoagulation–related intracranial hemorrhage: plasma transfusion is suggested. [1]
- Trauma with massive transfusion and plasma:RBC ratio ≥1:3: no recommendation can be made for or against using this ratio as a general practice. [1]
- Surgery or trauma without massive transfusion: plasma transfusion cannot be recommended for or against. [1]
- Warfarin anticoagulation reversal without intracranial hemorrhage: plasma transfusion cannot be recommended for or against. [1]
- Other scenarios without bleeding or without massive transfusion (examples listed by AABB include acute pancreatitis, organophosphate poisoning, and coagulopathy with acetaminophen overdose): AABB suggests against plasma transfusion in the available evidence base. [1]
- Prophylactic plasma transfusion in the absence of coagulopathy: AABB suggests against plasma transfusion. [1]
Key Evidence Supporting These Recommendations
- Trauma massive transfusion: plasma use was associated with reduced mortality in observational data, with an odds ratio of 0.38 (95% CI 0.24 to 0.60) in plasma:RBC ratios >1:3 (not a randomized comparison). [1]
- Plasma:RBC ratio ≥1:3 during massive transfusion: increased risk of acute lung injury was reported with higher plasma use, with an odds ratio of 2.92 (95% CI 1.99 to 4.29). [1]
- Warfarin-related intracranial hemorrhage: observational data reported that transfusion of 300 to 600 mL of plasma was associated with reduced mortality, with an odds ratio of 0.29 (95% CI 0.09 to 0.98). [1]
- Prophylactic plasma without coagulopathy: AABB-reported evidence showed increased mortality in two studies, with an odds ratio of 2.00 (95% CI 1.11 to 3.59). [1]
Monotherapy Versus Combination Therapy
- Warfarin intracranial hemorrhage: plasma transfusion is suggested as part of care for this scenario. [1]
- Warfarin reversal without intracranial hemorrhage: AABB cannot recommend plasma transfusion for reversal in the absence of intracranial hemorrhage. [1]
Important Clarifications and Nuances
- Plasma use based solely on abnormal coagulation tests without a defined bleeding or massive-transfusion context was specifically addressed as a scenario lacking supportive evidence and associated with harm in available studies. [1]
- AABB identified insufficient data to recommend an appropriate plasma dose for most of the clinical indications studied. [1]
Initiation Thresholds and Clinical Criteria
- Massive transfusion definition used in the guideline evidence summary: transfusion of 10 or more RBC units. [1]
- Plasma:RBC ratio threshold evaluated in trauma massive transfusion studies: ≥1:3 (the guideline does not support a general recommendation for this ratio). [1]
- Volume reported in the warfarin intracranial hemorrhage evidence summary: 300 to 600 mL plasma was associated with mortality reduction in a retrospective analysis. [1]
Common Pitfalls to Avoid
- Prophylactic plasma transfusion in the absence of coagulopathy: AABB suggests against this practice due to increased mortality observed in included studies. [1]
- Routine plasma transfusion during surgery or invasive procedures without massive transfusion: AABB cannot recommend for or against plasma transfusion due to very low-quality evidence in this scenario. [1]
- Applying plasma:RBC ratio ≥1:3 as a default standard during massive transfusion: AABB cannot recommend for or against this practice outside well-designed randomized trials. [1]
Targets or Goals of Therapy
No AABB target INR or other coagulation target thresholds for initiating or discontinuing plasma were specified in the evidence-based plasma transfusion guideline document. [1]
Administration-Related Considerations in the AABB Evidence Base
The AABB plasma transfusion guideline document evaluated clinical-use indications and evidence quality and reported that the available data were insufficient to recommend appropriate plasma dosing for most studied indications. [1]